165 related articles for article (PubMed ID: 35890364)
1. Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers.
Yalamarty SSK; Filipczak N; Li X; Pathrikar TV; Cotter C; Torchilin VP
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890364
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal Antibody 2C5-Modified Mixed Dendrimer Micelles for Tumor-Targeted Codelivery of Chemotherapeutics and siRNA.
Pan J; Attia SA; Subhan MA; Filipczak N; Mendes LP; Li X; Kishan Yalamarty SS; Torchilin VP
Mol Pharm; 2020 May; 17(5):1638-1647. PubMed ID: 32233497
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.
Yalamarty SSK; Filipczak N; Pathrikar T; Cotter C; Ataide JA; Luther E; Paranjape S; Torchilin V
Drug Deliv Transl Res; 2024 Aug; 14(8):2171-2185. PubMed ID: 38507033
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.
Yalamarty SSK; Filipczak N; Pathrikar T; Cotter C; Ataide JA; Luther E; Paranjape S; Torchilin V
Res Sq; 2023 Dec; ():. PubMed ID: 38168301
[TBL] [Abstract][Full Text] [Related]
5. Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.
Pan J; Mendes LP; Yao M; Filipczak N; Garai S; Thakur GA; Sarisozen C; Torchilin VP
Eur J Pharm Biopharm; 2019 Mar; 136():18-28. PubMed ID: 30633973
[TBL] [Abstract][Full Text] [Related]
6. Charge reversible hyaluronic acid-modified dendrimer-based nanoparticles for siMDR-1 and doxorubicin co-delivery.
Zhang X; Pan J; Yao M; Palmerston Mendes L; Sarisozen C; Mao S; Torchilin VP
Eur J Pharm Biopharm; 2020 Sep; 154():43-49. PubMed ID: 32645383
[TBL] [Abstract][Full Text] [Related]
7. Effects of the surface charge of polyamidoamine dendrimers on cellular exocytosis and the exocytosis mechanism in multidrug-resistant breast cancer cells.
Zhang J; Li M; Wang M; Xu H; Wang Z; Li Y; Ding B; Gao J
J Nanobiotechnology; 2021 May; 19(1):135. PubMed ID: 33980270
[TBL] [Abstract][Full Text] [Related]
8. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
9. PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells.
Sarisozen C; Vural I; Levchenko T; Hincal AA; Torchilin VP
Drug Deliv; 2012 May; 19(4):169-76. PubMed ID: 22506922
[TBL] [Abstract][Full Text] [Related]
10. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery.
Biswas S; Deshpande PP; Navarro G; Dodwadkar NS; Torchilin VP
Biomaterials; 2013 Jan; 34(4):1289-301. PubMed ID: 23137395
[TBL] [Abstract][Full Text] [Related]
11. Distinctive polymer micelle designed for siRNA delivery and reversal of MDR1 gene-dependent multidrug resistance.
Zhang CG; Yang SD; Zhu WJ; You BG; Liu Y; Yuan ZQ; Chen WL; Li JZ; Zhou XF; Liu C; Zhang XN
J Biomed Mater Res B Appl Biomater; 2017 Oct; 105(7):2093-2106. PubMed ID: 27405391
[TBL] [Abstract][Full Text] [Related]
12. Silencing of HMGA2 by siRNA Loaded Methotrexate Functionalized Polyamidoamine Dendrimer for Human Breast Cancer Cell Therapy.
Abedi Gaballu F; Cho WC; Dehghan G; Zarebkohan A; Baradaran B; Mansoori B; Abbaspour-Ravasjani S; Mohammadi A; Sheibani N; Aghanejad A; Ezzati Nazhad Dolatabadi J
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356120
[TBL] [Abstract][Full Text] [Related]
13. PAMAM G4.5 dendrimers for targeted delivery of ferulic acid and paclitaxel to overcome P-glycoprotein-mediated multidrug resistance.
Anbazhagan R; Muthusamy G; Krishnamoorthi R; Kumaresan S; Rajendra Prasad N; Lai JY; Yang JM; Tsai HC
Biotechnol Bioeng; 2021 Mar; 118(3):1213-1223. PubMed ID: 33289076
[TBL] [Abstract][Full Text] [Related]
14. Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery.
Xu L; Yeudall WA; Yang H
Acta Biomater; 2017 Jul; 57():251-261. PubMed ID: 28438704
[TBL] [Abstract][Full Text] [Related]
15. The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles.
Zou W; Sarisozen C; Torchilin VP
J Drug Target; 2017 Mar; 25(3):225-234. PubMed ID: 27616277
[TBL] [Abstract][Full Text] [Related]
16. Modulated cellular delivery of anti-VEGF siRNA (bevasiranib) by incorporating supramolecular assemblies of hydrophobically modified polyamidoamine dendrimer in stealth liposomes.
Golkar N; Samani SM; Tamaddon AM
Int J Pharm; 2016 Aug; 510(1):30-41. PubMed ID: 27291973
[TBL] [Abstract][Full Text] [Related]
17. Tumor-targeting pH/redox dual-responsive nanosystem epigenetically reverses cancer drug resistance by co-delivering doxorubicin and GCN5 siRNA.
Yuan Y; Liu J; Yu X; Liu X; Cheng Y; Zhou C; Li M; Shi L; Deng Y; Liu H; Wang G; Wang L; Wang Z
Acta Biomater; 2021 Nov; 135():556-566. PubMed ID: 34496281
[TBL] [Abstract][Full Text] [Related]
18. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
Gu J; Fang X; Hao J; Sha X
Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
20. pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1.
Benoit DS; Henry SM; Shubin AD; Hoffman AS; Stayton PS
Mol Pharm; 2010 Apr; 7(2):442-55. PubMed ID: 20073508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
